These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 25230982)
21. A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy. Duan Y; Zheng J; Han S; Wu Y; Wang Y; Li D; Kong D; Yu Y J Control Release; 2008 Apr; 127(2):173-9. PubMed ID: 18316136 [TBL] [Abstract][Full Text] [Related]
22. Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody. Chrastina A; Pastoreková S; Pastorek J Neoplasma; 2003; 50(1):13-21. PubMed ID: 12687273 [TBL] [Abstract][Full Text] [Related]
23. The expression of G250/mn/CA9 antigen by flow cytometry: its possible implication for detection of micrometastatic renal cancer cells. Li G; Passebosc-Faure K; Lambert C; Gentil-Perret A; Blanc F; Oosterwijk E; Mosnier JF; Genin C; Tostain J Clin Cancer Res; 2001 Jan; 7(1):89-92. PubMed ID: 11205923 [TBL] [Abstract][Full Text] [Related]
28. Enhanced Therapeutic Activity of Non-Internalizing Small-Molecule-Drug Conjugates Targeting Carbonic Anhydrase IX in Combination with Targeted Interleukin-2. Cazzamalli S; Ziffels B; Widmayer F; Murer P; Pellegrini G; Pretto F; Wulhfard S; Neri D Clin Cancer Res; 2018 Aug; 24(15):3656-3667. PubMed ID: 29691298 [No Abstract] [Full Text] [Related]
29. A pilot study of monoclonal antibody cG250 and low dose subcutaneous IL-2 in patients with advanced renal cell carcinoma. Davis ID; Liu Z; Saunders W; Lee FT; Spirkoska V; Hopkins W; Smyth FE; Chong G; Papenfuss AT; Chappell B; Poon A; Saunder TH; Hoffman EW; Old LJ; Scott AM Cancer Immun; 2007 Aug; 7():14. PubMed ID: 17705350 [TBL] [Abstract][Full Text] [Related]
30. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Davis ID; Wiseman GA; Lee FT; Gansen DN; Hopkins W; Papenfuss AT; Liu Z; Moynihan TJ; Croghan GA; Adjei AA; Hoffman EW; Ingle JN; Old LJ; Scott AM Cancer Immun; 2007 Aug; 7():13. PubMed ID: 17705349 [TBL] [Abstract][Full Text] [Related]
31. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Ahlskog JK; Schliemann C; Mårlind J; Qureshi U; Ammar A; Pedley RB; Neri D Br J Cancer; 2009 Aug; 101(4):645-57. PubMed ID: 19623173 [TBL] [Abstract][Full Text] [Related]
32. Preliminary biological evaluation of ¹²⁵I-labeled anti-carbonic anhydrase IX monoclonal antibody in the mice bearing HT-29 tumors. Li J; Shi L; Wang C; Zhang X; Jia L; Li X; Zhou W; Qi Y; Zhang L Nucl Med Commun; 2011 Dec; 32(12):1190-3. PubMed ID: 21968435 [TBL] [Abstract][Full Text] [Related]
33. [Fusion expression of human renal cell carcinoma-associated antigen G250/MN/CA IX in prokaryotic expression system]. Jiang YD; Zheng SB; Tan WL; Zhao SC; Ren F; Zhang B Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar; 27(3):307-9. PubMed ID: 17425979 [TBL] [Abstract][Full Text] [Related]
34. Quantification of G250 mRNA expression in renal epithelial neoplasms by real-time reverse transcription-PCR of dissected tissue from paraffin sections. Bismar TA; Bianco FJ; Zhang H; Li X; Sarkar FH; Sakr WA; Grignon DJ; Che M Pathology; 2003 Dec; 35(6):513-7. PubMed ID: 14660102 [TBL] [Abstract][Full Text] [Related]
35. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor. Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814 [TBL] [Abstract][Full Text] [Related]
36. Soluble carbonic anhydrase IX is not an independent prognostic factor in human renal cell carcinoma. Papworth K; Sandlund J; Grankvist K; Ljungberg B; Rasmuson T Anticancer Res; 2010 Jul; 30(7):2953-7. PubMed ID: 20683038 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Petrul HM; Schatz CA; Kopitz CC; Adnane L; McCabe TJ; Trail P; Ha S; Chang YS; Voznesensky A; Ranges G; Tamburini PP Mol Cancer Ther; 2012 Feb; 11(2):340-9. PubMed ID: 22147747 [TBL] [Abstract][Full Text] [Related]